Clinical trials: Head and Neck Squamous Cell Carcinomas
Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent…
- Trial name
- CPI (NCT07633613)
- Testing
- Blood sampling, Tumor biopsies for biobank establishment (optional)
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Esophageal Squamous Cell Carcinoma
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Abstract Objective: This study aims to investigate the potential clinical impact of neoadjuvant immunotherapy in resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06388135
- Testing
- Serplulimab Combined With Nab-paclitaxel and Cisplatin, nab-paclitaxel，Cisplatin
- Volunteers
- 80 people
- Sponsor
- Yang Jianjun, PhD
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
- Trial name
- NCT03237325
- Testing
- SGX942
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 266 people
- Sponsor
- Soligenix
Oral Cavity Cancer
Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers
Surgical margin is a significant prognostic factor in oral cavity squamous cell carcinoma (OCSCC)[1,2,3]. Intra-operative frozen section (FS) has been routinely used by the surgeons to achieve adequate surgical margins.
- Trial name
- NCT04809324
- Testing
- Gross examination of the resection specimen, Frozen section
- Where
- 3 sites in India
- Volunteers
- 1,206 people
- Sponsor
- Dr.Pankaj Chaturvedi
Esophageal Squamous Cell Carcinoma
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with…
- Trial name
- NCT06988956
- Testing
- Nimotuzumab, Tegafur, radiotherapy
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Head and Neck Cancer, Head Cancer
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer…
- Conditions
- Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer
- Trial name
- NCT04722523
- Testing
- Cisplatin, Carboplatin, Docetaxel
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Head and Neck Squamous Cell Carcinoma
the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer
This study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic…
- Trial name
- NCT03196869
- Testing
- Chrono-chemotherapy, Routine intravenous drip, induction Chrono-chemotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Guiyang Medical University
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Recurrent Cancer, Prostate Cancer
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.
- Conditions
- Recurrent Cancer, Prostate Cancer, Cervical Cancer, Anal Cancer
- Trial name
- HETERERO (NCT04889742)
- Testing
- loco-regional hyperthermia
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Charite University, Berlin, Germany
Squamous Cell Carcinoma of the Head and Neck
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer.
- Trial name
- NCT03690986
- Testing
- VX15/2503, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Emory University
Head and Neck Cancer
Can DW MRI Predict Outcome During Radiotherapy for Head and Neck Cancer?
Around 50% of patients with locally advanced H\&N cancer fail to achieve loco-regional control. Currently it cannot be predicted, during treatment, who will fall into this group of non-responders.
- Trial name
- MeRInO (NCT02497573)
- Testing
- Diffuse Weighted MRI
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- NHS Greater Glasgow and Clyde
Cancer, Solid Malignant Tumors
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature…
- Conditions
- Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC
- Trial name
- NCT06915454
- Testing
- Intra-op PET/CT Specimen Scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer, Carcinoma, Squamous Cell
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck cancer who cannot tolerate chemotherapy.
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
- Trial name
- NCT00490061
- Testing
- Lapatinib, Radiotherapy (radiation), G.E. Healthcare 1.5T MR, systems revision 12.0 M5
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Quynh-Thu Le
Esophageal Squamous Cell Carcinoma
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma are recruited to this prospective non-randomized study comprising two separate cohorts.
- Trial name
- NCT03603756
- Testing
- SHR-1210, Apatinib, Irinotecan Injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
- Trial name
- NCT04616196
- Testing
- NKTR-255, Cetuximab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Squamous Cell Carcinoma of Head and Neck
Concurent Chemoradiotherapy in Head and Neck Cancers
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for…
- Trial name
- NCT04780750
- Testing
- Docetaxel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Esophageal Squamous Cell Carcinoma
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
NICE-RT study is a "safety run-in" and phase II trial evaluating the safety and efficacy of Camrelizumab combined with Nab-paclitaxel and Carboplatin and Radiotherapy in patients with resectable locally advanced esophageal…
- Trial name
- NCT05650216
- Testing
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Squamous Cell of Head and Neck
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer arising in the upper aerodigestive tract, and is the sixth leading incident cancer worldwide.
- Trial name
- NCT02277184
- Testing
- Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Julie E. Bauman, MD, MPH
Esophageal Cancer
A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer
The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell…
- Trial name
- NCT00995358
- Testing
- peptide
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- University of Yamanashi
HNSCC
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.
- Trial name
- NCT04340258
- Testing
- Cesium-131, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.